Establishment of nucleophosmin gene silenced HL-60 and its resistant cell line.
- Author:
Min-Hui LIN
1
;
Jian-Da HU
Author Information
1. Fujian Medical University Union Hospital, Fujian Institute of Hematology, Fujian Province, China.
- Publication Type:Journal Article
- MeSH:
Cell Line, Tumor;
Doxorubicin;
pharmacology;
Drug Resistance, Neoplasm;
genetics;
Genetic Vectors;
HL-60 Cells;
Humans;
Lentivirus;
genetics;
Nuclear Proteins;
genetics;
RNA Interference
- From:
Journal of Experimental Hematology
2011;19(6):1393-1398
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to construct model cell line of NPM1-RNAi in HL-60 cells and its resistant line (HL-60/ADR) so as to provide a experimental basis for investigating the potential role of NPM1 gene in leukemia drug resistance. The shRNA targeting to NPM1 was ligated into linear pGCSIL-GFP vector, and transformed into E.coli DH5α. Positive clone was identified by PCR and DNA sequencing. pHelper 1.0, pHelper 2.0 and pGCSIL-GFP-NPM1-shRNA were cotransformed into 293T cells by lentivirus vector system. NPM1-RNAi-LV was transfected into HL-60 and HL-60/ADR cell lines. The efficiency of NPM-RNAi-LV was detected by using real-time quantitative RT-PCR and Western blot. The results showed that the recombinant eukaryotic expression vector pGCSIL-GFP-NPM1-shRNA was constructed. pGCSIL-GFP-NPM1-shRNA was packed into NPM1-RNAi-LV by lentivirus vector system, and transfected into HL-60 and HL-60/ADR cell lines. At mRNA level, the efficiency of NPM1 mRNA knockdown was more than 90% (p < 0.05). At protein level, obvious down-regulation of NPM protein was noted, indicating that NPM1 gene in HL-60 and HL-60/ADR cell lines was knocked down after transfected with NPM1-RNAi-LV. The resistance of HL-60/ADR cell line to adriamycin decreased to a certain degree after NPM1 gene silencing. It is concluded that the model cell lines of NPM1-RNAi in HL-60 and HL-60/ADR are successfully constructed, which can be used for investigating the potential role of NPM1 gene in drug resistance of leukemia.
